GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Urinary Bladder Cancer; Melanoma; Sarcoma Interventions: Drug: GI-101; Drug: Pembrolizumab; Drug: Lenvatinib; Radiation: Local Radiotherapy Sponsors: GI Innovation, Inc.; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials